# Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant

> **NCT00003894** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 36 (actual)

## Conditions studied

- Graft Versus Host Disease
- Unspecified Adult Solid Tumor, Protocol Specific
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00003894
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2000-01
- **Final completion:** 2002-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2011-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003894, "Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00003894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*